BDR Pharma launches Enzalutamide under the brand name BDENZA
The objective behind the launch of Enzalutamide 160 mg is to ensure better efficacy and minimum side effects.
New Delhi: BDR Pharmaceuticals on Monday said it has launched prostate cancer treatment drug Enzalutamide in 160 mg strength. The company has introduced the medication, under the brand name BDENZA 160mg, at Rs 6,300 for a strip of seven tablets.
The medicine was previously available in 40 mg and 80 mg strength for which patients had to consume two tablets a day.
The objective behind the launch of Enzalutamide 160 mg is to ensure better efficacy, minimum side effects, contain relapse cases by blocking the hormones of cancer cells providing an evolved treatment, BDR Pharmaceuticals said in a statement.
"Our focused launch of such expanded brand strength will definitely add value to Indian oncology patients as well as provide opportunity for medical physicians to comply with patient outcome and standard treatment protocol.
"This represents a firm commitment to providing access to affordable medicines for Indian cancer patients with high quality standards," BDR Pharmaceuticals Director Business Development Raheel Shah noted.
BDR Group of companies has grown steadily and become a house-hold name in the pharmaceutical Industry over the last 15 years, in both domestic and international arenas. The company is recognized as a "niche" player in the manufacturing of Pharmaceutical APIs and for our renowned new age formulations. The group is complemented majorly by its two companies - BDR Pharmaceuticals International Pvt Ltd and BDR Life sciences Pvt. Ltd, each one has stamped its own supremacy in respective fields, i.e. API and formulation manufacturing, respectively. BDR Group focuses on development in 4 specialized therapeutic segments, viz. Oncology, Critical care, Gynecology & Neurology, which are its dream segments.BDR now has ambitious plans to manufacture specialized Oncological Injectable dosage forms as the next giant step.
Next Story